This is a clinical trial for adults with advanced solid tumors that have continued to grow despite the treatments already received.

The major purposes of this study are to determine the highest dose of the investigational drug RNK05047 that can be safely taken, evaluate the overall safety of RNK05047, measure the amount of RNK05047 in the blood following treatment, and evaluate if RNK05047 has any effect against cancer.
   
RNK05047 is an experimental drug designed to try to kill cancer cells by removing a protein called BRD4. An experimental drug is one that is being tested and is not -approved by the United States Food and Drug Administration (FDA). 
   
RNK05047 is given intravenously through a vein in the arm once per week for 3 weeks followed by 1 week in which no drug is given. 
   
The duration of study participation is approximately 4 months. During that time, participants will have about 26 study visits. Participation in the study may be shorter or longer depending on how each participant's cancer is responding to the study drug.